Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Oral oncology"
DOI: 10.1016/j.oraloncology.2017.05.012
Abstract: OBJECTIVES Low skeletal muscle mass (SMM) or sarcopenia is emerging as an adverse prognostic factor for chemotherapy dose-limiting toxicity (CLDT) and survival in cancer patients. Our aim was to determine the impact of low SMM… read more here.
Keywords: low smm; smm; mass; factor ... See more keywords